ReviewJournal of clinical medicine2021
Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Insights and limitations of endometrial cancer risk prediction models for clinical applicability: a systematic review.BMC cancer · 2025Pooled it
- Association of endometrial cancer risk with hypertension- an updated meta-analysis of observational studies.Scientific reports · 2024Pooled it
- Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Review
- A Retrospective Cohort Study of Uterine Cancer Epidemiological Analysis and Age-Based Disparities in Saudi Arabian Population across 32 Years.Saudi medical journal · 2026Article
- Review
- Metabolomics Analysis-Based Machine Learning for Endometrial Cancer Diagnosis: Integration of Biomarker Discovery and Explainable Artificial Intelligence.Journal of clinical practice and research · 2025Article
- Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure.Japanese journal of clinical oncology · 2025Review
- Menopause in gynecologic cancer survivors: evidence for decision-making.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025Review
- Prospective cohort of pre-diagnosis hormone exposure and post-diagnosis sex hormone levels with survival outcomes: Alberta Endometrial Cancer Cohort Study.Endocrine oncology (Bristol, England) · 2025Article
- Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records.British journal of cancer · 2024Article
- Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.Journal of gynecologic oncology · 2024Article
- Hormone Replacement Therapy in Post-Menopause Hormone-Dependent Gynecological Cancer Patients: A Narrative Review.Journal of clinical medicine · 2024Review
- A case of solitary lymph node recurrence 9 years after initial treatment for advanced premenopausal endometrioid endometrial cancer; clinical usefulness of hormonal replacement therapy.International cancer conference journal · 2023Article
- An implementation of the learning curve cumulative summation test to evaluate a practicum for endometrial cancer ultrasound staging.Ultrasonography (Seoul, Korea) · 2023Article
- Quantification of Women Who Could Benefit from Hormone Therapy after Endometrial Cancer Treatment: An Analysis of SEER Data.Current oncology (Toronto, Ont.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study is to investigate the effect of hormone therapy (HT) on the oncological outcomes of endometrial cancer (EC) survivors. A systematic literature review was conducted in July 2021 to identify studies detailing the effect size for the relationship between HT use in EC and oncological outcomes (survival and disease recurrence). This included studies that evaluated the different recurrence rates among women treated for EC who subsequently underwent HT and those who did not. The collected studies were evaluated for quality, heterogeneity, and publication bias, and a pooled odds ratio (OR) or hazard ratio (HR) was calculated with a confidence interval of 95% (95% CI). In total, 5291 studies were collated, and after the review process, one randomized trial and seven observational studies were included, comprising 1801 EC survivors treated with HT and 6015 controls. The time-dependent analysis could be conducted for four studies, and considering the disease-free survival, the pooled HR of 0.90 (95% CI 0.28 to 2.87) showed no significant differences. However, among Black American women treated with continuous estrogen HT, the HR was 7.58 (95% CI 1.96 to 29.31), showing a significantly increased risk of recurrence for women in this ethnic group. Considering the pooled OR of all included studies 0.63 (95% CI 0.48 to 0.83), a significantly reduced risk of recurrence was found among EC survivors treated with HT. Considering the type of HT, the most risk-reducing was combined estrogen and progestin therapy and the cyclic regimen. Although supporting evidence is based mainly upon observational studies, evidence of no increased risk or even decreased risk was generally found, apart from in Black American women where a significantly increased recurrence risk was evident. The data are rather reassuring for the short-term administration of HT to symptomatic EC survivors. Future studies with a longer follow-up are necessary to better clarify the long-term effects of HT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.